COVID-19 Oral Vaccine Producer Under U.S. SEC Scrutiny

California-based Vaxart Inc. disclosed in its legal filings on October 13, 2020, that it has come under scrutiny from federal prosecutors and the US Securities and Exchange Commission. Vaxart stated it had received a subpoena from the US Justice Department concerning its role in Operation Warp Speed program, and other related matters.

Vaxart's VXA-CoV2-1 oral vaccine candidate is indicated to prevent the new SARS-CoV-2 coronavirus, which causes COVID-19 disease in humans.